Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)

Arnon P. Kater, J Christine Ye, Jose Sandoval-Sus, Mar Bellido, Jacob Haaber Christensen, Anthony R. Mato, Ann Janssens, Toshihiko Oki, Daniela Hoehn, Marcia Rios, Alexandra Kuznetsova, Rebecca Valentin, Herbert Eradat

Blood (2022) 140 (Supplement 1): 850–851.

https://doi.org/10.1182/blood-2022-158298

Published: 2022

Journal Articles

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Leon Bernal-Mizrachi, Ajay K. Nooka, Leonard Heffner, Craig E. Cole, Ravi Vij, J Christine Ye, Craig C Hofmeister, John Rushton, Zhengjia Chen, Subir Goyal, Munevver Cinar, Sagar Lonial, Jonathan L. Kaufman

Blood (2022) 140 (Supplement 1): 7311–7312.

https://doi.org/10.1182/blood-2022-170062

Published: 2022

Journal Articles

Initial Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-553, a Novel and Selective PKCβ Inhibitor, in Patients with CLL/SLL

James S. Blachly, Deborah M. Stephens, J Christine Ye, Nicole Lamanna, Nitin Jain, Michael Niesman, Kai Zhang, Jennifer A. Woyach

Blood (2022) 140 (Supplement 1): 2324–2325.

https://doi.org/10.1182/blood-2022-171203

Published: 2022

Journal Articles

Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Christopher T Su, MD, Liying Chen, MS, Jason Chen, MD, Brian Parkin, MD, Avery Polk, Malathi Kandarpa, PhD, Craig E. Cole, MD, Erica Campagnaro, MD, Josh Vo, PhD, Dan Robinson, PhD, Yi-Mi Wu, PhD, Moshe Talpaz, MD, Jennifer Yesil, MSc, Daniel Auclair, P. Leif Bergsagel, MD, Arul Chinnaiyan, MDPhD, Veerabhadran Baladandayuthapani, PhD, J Christine Ye, MDMSc

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-134558

Published: 2020

Journal Articles

A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia

Kerry A Rogers, MD, Lai Wei, PhD, Seema A. Bhat, MD, Dan Jones, MD PhD, Erlene K. Seymour, MD, Deborah M. Stephens, DO, J Christine Ye, MDMSc, John C. Byrd, MD, Jennifer Woyach, MD

Blood (2019) 134 (Supplement_1): 3049.

https://doi.org/10.1182/blood-2019-125360

Published: 2019

Journal Articles

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Stephen D. Smith, MD, Javier Munoz, MD MS, FACP, Don Stevens, MD, Sonali M. Smith, MD, Tatyana A. Feldman, MD, J Christine Ye, MDMSc, Sven de Vos, MD PhD, Brian T. Hess, MD, Carole B. Miller, MD, James L. Khatcheressian, MD, Matt R. Birrell, Janet M. Leeds, PhD, Gregory P. Coffey, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 3981.

https://doi.org/10.1182/blood-2019-124231

Published: 2019

Journal Articles

Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients

J Christine Ye, MDMSc, Liying Chen, Jason Chen, MD, Brian Parkin, Avery Polk, Malathi Kandarpa, PhD, Craig E. Cole, MD, Erica L. Campagnaro, MD, Dan Robinson, PhD, Yi-Mi Wu, Moshe Talpaz, MD, Jennifer Yesil, Daniel Auclair, P. Leif Bergsagel, MD, Arul Chinnaiyan, MD, Veerabhadran Baladandayuthapani

Blood (2019) 134 (Supplement_1): 4360.

https://doi.org/10.1182/blood-2019-124135

Published: 2019

Journal Articles

A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy

J Christine Ye, MDMSc, Philip S Boonstra, PhD, Daniel F. Boyer, MD PhD, Larry D. Anderson, MD PhD, Brea C. Lipe, MD, Andrew Kin, MD, Erica L. Campagnaro, MD, Matthew J. Pianko, MD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 3191.

https://doi.org/10.1182/blood-2019-132204

Published: 2019

Journal Articles

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Leon Bernal-Mizrachi, MD, Ajay K Nooka, MDMPH, Leonard Heffner, MD, Craig E. Cole, MD, J Christine Ye, MDMSc, Ravi Vij, MBBS, Craig C Hofmeister, MDMPH, John Rushton, PhD, Zhengjia Chen, PhD, Zhao Chang, PhD, Munevver Cinar, MD, Daniel Auclair, Sagar Lonial, Jonathan L. Kaufman, MD

Blood (2019) 134 (Supplement_1): 3188.

https://doi.org/10.1182/blood-2019-131223

Published: 2019

Journal Articles

Outcomes in Patients on Hemodialysis Who Undergo High Dose Therapy Followed By Autologous Peripheral Blood Stem Cell Transplant for Multiple Myeloma in the Era of Novel Agents

J. Christine Ye, MD MSc, Lakshminarayanan Nandagopal, MD, Marie Ventimiglia, Muneer H. Abidi, MD, Lois Ayash, MD, Lawrence G Lum, MD DSc, Joseph P. Uberti, MD PhD, Voravit Ratanatharathorn, MD, Jeffrey Zonder, MD, Divaya Bhutani, MD, Abhinav Deol, MD

Blood (2014) 124 (21): 2518.

https://doi.org/10.1182/blood.V124.21.2518.2518

Published: 2014

Journal Articles

Outcomes of Second Autologous Peripheral Blood Stem Cell Transplant in Multiple Myeloma Patients with Renal Dysfunction

Lakshminarayanan Nandagopal, MD, J. Christine Ye, MD MSc, Richard Manasa, BS, Muneer H. Abidi, MD, Lois Ayash, MD, Lawrence G Lum, MD DSc, Joseph P. Uberti, MD PhD, Voravit Ratanatharathorn, MD, Jeffrey Zonder, MD, Divaya Bhutani, MD, Abhinav Deol, MD

Blood (2014) 124 (21): 5894.

https://doi.org/10.1182/blood.V124.21.5894.5894

Published: 2014

Journal Articles

Influence of Race on Outcomes in Multiple Myeloma Patients with Renal Dysfunction Undergoing High Dose Therapy Followed By Autologous Stem Cell Transplant

Lakshminarayanan Nandagopal, MD, J. Christine Ye, MD MSc, Marie Ventimiglia, Muneer H. Abidi, MD, Lois Ayash, MD, Jeffrey Zonder, MD, Lawrence G Lum, MD DSc, Joseph P. Uberti, MD PhD, Voravit Ratanatharathorn, MD, Divaya Bhutani, MD, Abhinav Deol, MD

Blood (2014) 124 (21): 5904.

https://doi.org/10.1182/blood.V124.21.5904.5904

Published: 2014

NARROW

Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Initial Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-553, a Novel and Selective PKCβ Inhibitor, in Patients with CLL/SLL

Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM)

A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients

A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Outcomes in Patients on Hemodialysis Who Undergo High Dose Therapy Followed By Autologous Peripheral Blood Stem Cell Transplant for Multiple Myeloma in the Era of Novel Agents

Outcomes of Second Autologous Peripheral Blood Stem Cell Transplant in Multiple Myeloma Patients with Renal Dysfunction

Influence of Race on Outcomes in Multiple Myeloma Patients with Renal Dysfunction Undergoing High Dose Therapy Followed By Autologous Stem Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only